Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Chelim Cheong"'
Autor:
Su-Yeon Yu, Miyoung Choi, Chelim Cheong, Seungeun Ryoo, Kyungmin Huh, Young Kyung Yoon, Jungwoo Choi, Sun Bean Kim
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 56, Iss 5, Pp 909-920 (2023)
This study evaluated the efficacy and safety of neutralizing monoclonal antibodies (mAbs) with usual care in patients with coronavirus disease 2019 (COVID-19). Randomized controlled trials comparing the efficacy and safety of neutralizing mAb treatme
Externí odkaz:
https://doaj.org/article/12f82cb71a8045618d082086e2857018
Autor:
Won Suk Choi, Yeonhee Sung, Jimin Kim, Hyeri Seok, Young J. Choe, Chelim Cheong, Jahyun Cho, Dong Woo Lee, Jee Yeon Shin, Su-Yeon Yu
Publikováno v:
Vaccines, Vol 12, Iss 8, p 886 (2024)
This study presents a framework for determining the prioritization of vaccine introduction in the National Immunization Program (NIP) of the Republic of Korea, with a focus on case examples assessed in 2021 and 2023. We describe the predefined criter
Externí odkaz:
https://doaj.org/article/34943a9b6b4f481e885be3d4b540e624
Autor:
Su-Yeon Yu, Miyoung Choi, Seungeun Ryoo, Chelim Cheong, Kyungmin Huh, Young Kyung Yoon, Su Jin Jeong
Publikováno v:
PLoS ONE, Vol 18, Iss 11, p e0294872 (2023)
Inhaled corticosteroids are known to be relatively safe for long-term use in inflammatory respiratory diseases and it has been repurposed as one of the potential therapies for outpatients with coronavirus disease 2019 (COVID-19). However, inhaled cor
Externí odkaz:
https://doaj.org/article/4e7337142bf343b7b2a8ee3558b07e54
Autor:
Tae-Jin Lee, Chelim Cheong
Publikováno v:
Journal of Preventive Medicine and Public Health, Vol 50, Iss 6, Pp 393-400 (2017)
Objectives To relieve the financial burden faced by households, the Korean National Health Insurance (NHI) system introduced a “copayment ceiling,” which evolved into a differential ceiling in 2009, with the copayment ceiling depending on patient
Externí odkaz:
https://doaj.org/article/bfdaf71b5b5b4cfea56aa174ff8b5970
Autor:
Chelim Cheong, Tae-Jin Lee
Publikováno v:
Epidemiology and Health, Vol 36 (2014)
OBJECTIVES Despite the clinical and epidemiological importance of herpes zoster (HZ) and postherpetic neuralgia (PHN), their disease and economic burden related to immune status has not been studied in South Korea. Our aim was to calculate the preval
Externí odkaz:
https://doaj.org/article/f5e103ef3269403b94af5550c0394ea2
Autor:
Jimin Kim, Young June Choe, Jungeun Park, Jahyun Cho, Chelim Cheong, Jin-Kyoung Oh, Mihai Park, Eunha Shim, Su-Yeon Yu
Publikováno v:
Infection & Chemotherapy; Mar2024, Vol. 56 Issue 1, p37-46, 10p
Publikováno v:
Pediatric Infection & Vaccine. 29:28
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81c88c6cc841a6d9c9f777f7187386fd
https://doi.org/10.14776/piv.2022.29.e4
https://doi.org/10.14776/piv.2022.29.e4
Publikováno v:
The American journal of managed care. 23(9)
Specialty drugs can bring significant benefits to patients, but they can be expensive. Medicare Part D plans charge relatively high cost-sharing costs for specialty drugs. A provision in the Affordable Care Act reduced cost sharing in the Part D cove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::214501c1f6c02e5a7e6ed38ba423a7cc
https://pubmed.ncbi.nlm.nih.gov/29087157
https://pubmed.ncbi.nlm.nih.gov/29087157
Publikováno v:
The American journal of managed care. 22(6 Spec)
The recent arrival of new hepatitis C virus (HCV) drugs has brought fiscal pressures onto Medicare Part D; spending on HCV drugs in Part D jumped from $283 million in 2013 to $4.5 billion in 2014. We examined the current benefit designs for HCV drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dd5c27a4375ef29a6a01af94599b8bb4
https://pubmed.ncbi.nlm.nih.gov/27266952
https://pubmed.ncbi.nlm.nih.gov/27266952
Publikováno v:
Clinical Therapeutics. 30:1893-1907
Background: Little is known about the potential for improved adherence with and cost savings of fixed-dose combination therapy (FDCT) products compared with analogous dual therapy for type 2 diabetes mellitus. Objectives: The objectives of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::963406f789e6ca9df4041213b4d44009
https://doi.org/10.1016/j.clinthera.2008.10.003
https://doi.org/10.1016/j.clinthera.2008.10.003